Showing results (61-70 of 88) with videos related to

Sort By:
Pageof 9
Lupus|July 9, 2021
10 Years of belimumab experience: What have we learnt?Roger A Levy, Tania Gonzalez-Rivera, Munther Khamashta, et al.
Kidney International|April 29, 2026
Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritisBrad H Rovin, Richard Furie, Ana Malvar, et al.
Modern Rheumatology|October 8, 2022
Efficacy of belimumab in patients with systemic lupus erythematosus from North East Asia: Results of exploratory subgroup analysesJie Zheng, Jieruo Gu, Yin Su, et al.
Kidney International|September 24, 2021
A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritisBrad H Rovin, Richard Furie, Y K Onno Teng, et al.
Arthritis Research & Therapy|February 17, 2022
The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week studySang-Cheol Bae, Damon L Bass, Myron Chu, et al.
Blood|September 24, 2004
The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia BAmy D Shapiro, Jorge Di Paola, Alice Cohen, et al.
RMD Open|April 16, 2022
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 yearsFengchun Zhang, Jie Zheng, Yang Li, et al.
Environmental Science & Technology|January 3, 2022
Watershed-Scale Risk to Aquatic Organisms from Complex Chemical Mixtures in the Shenandoah RiverLarry B Barber, Kaycee E Faunce, David W Bertolatus, et al.
Molecular and Biochemical Parasitology|January 1, 2008
Transcriptionally active PCR for antigen identification and vaccine development: in vitro genome-wide screening and in vivo immunogenicityDavid P Regis, Carlota Dobaño, Paola Quiñones-Olson, et al.
Blood Advances|February 28, 2025
A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemiaFarhad Ravandi, Sravanti Rangaraju, Hagop Kantarjian, et al.
Pageof 9